As part of our series focussing on newly available medicines in Australia, we have added a product review of use of Vericiguat in the treatment of heart failure and reduced ejection fraction.
This review discusses pharmacological properties, mechanism of action, drug interactions and major studies featuring Vericiguat. It also provides commentary and recommendations from Associate Professor John Amerena, Cardiologist at Barwon Health and Director of the Geelong Cardiology Research Unit.
Please login below to download this issue (PDF)